Regeneron Pharmaceuticals Inc (REGN) — Cash Flow Quality Index
Regeneron Pharmaceuticals Inc (REGN) has a Cash Flow Quality Index of 0.44x as of June 2026. Operating cash flow of $574.50 Million is below net income of $1.30 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore REGN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Regeneron Pharmaceuticals Inc Cash Flow Quality Index (2004–2025)
Historical Cash Flow Quality Index for Regeneron Pharmaceuticals Inc across 15 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see REGN cash flow metrics.
Annual Cash Flow Quality Index for Regeneron Pharmaceuticals Inc (2004–2025)
Year-by-year earnings quality comparison for Regeneron Pharmaceuticals Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.11x | $4.98 Billion | $4.50 Billion | ▲ +10.3% |
| 2024 | 1.00x | $4.42 Billion | $4.41 Billion | ▼ -13.8% |
| 2023 | 1.16x | $4.59 Billion | $3.95 Billion | ▲ +0.5% |
| 2022 | 1.16x | $5.01 Billion | $4.34 Billion | ▲ +31.8% |
| 2021 | 0.88x | $7.08 Billion | $8.08 Billion | ▲ +17.7% |
| 2020 | 0.75x | $2.62 Billion | $3.51 Billion | ▼ -35.1% |
| 2019 | 1.15x | $2.43 Billion | $2.12 Billion | ▲ +27.9% |
| 2018 | 0.90x | $2.20 Billion | $2.44 Billion | ▼ -17.7% |
| 2017 | 1.09x | $1.31 Billion | $1.20 Billion | ▼ -34.3% |
| 2016 | 1.66x | $1.49 Billion | $895.52 Million | ▼ -20.7% |
| 2015 | 2.09x | $1.33 Billion | $636.06 Million | ▼ -3.2% |
| 2014 | 2.16x | $752.43 Million | $348.07 Million | ▲ +55.9% |
| 2013 | 1.39x | $588.60 Million | $424.36 Million | ▲ +1494.7% |
| 2012 | -0.10x | $-74.61 Million | $750.27 Million | ▲ +75.5% |
| 2004 | -0.41x | $-16.91 Million | $41.70 Million | — |